clonidine has been researched along with buspirone in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (28.13) | 18.7374 |
| 1990's | 7 (21.88) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Duncton, MA; Emerling, DE; Kelly, MG; Nguyen, MT; Vincent, F | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Devi, K; Hrishikeshavan, HJ; Munonyedi, US; Shanbhogue, RS | 1 |
| Hijzen, TH; Rijnders, HJ; Slangen, JL | 1 |
| Blier, P; Chaput, Y; Curet, O; de Montigny, C | 1 |
| Coke, JA; McMillen, BA; Sanghera, MK; Williams, HL | 1 |
| Dresse, A; Giesbers, I; Scuvée-Moreau, J | 1 |
| Engberg, G | 1 |
| Giral, P; Puech, AJ; Soubrie, P | 1 |
| Bianchi, G; Garattini, S | 1 |
| Bianchi, G; Caccia, S; Della Vedova, F; Garattini, S | 1 |
| Geiger, G; Grimes, D; Heaslip, RJ; Henry, DE; Lee, DK; Rimele, TJ | 1 |
| Altesman, RI; Cole, JO | 1 |
| Rickels, K | 1 |
| German, DC; Sanghera, MK | 1 |
| Berlin, I; Cesselin, F; Chalon, S; Payan, C; Puech, AJ; Schöllnhammer, G; Varoquaux, O | 1 |
| Cao, BJ; Li, WP | 1 |
| Luo, ZP; Zhang, HT | 1 |
| Adams, DP; Covey, LS; Glassman, AH; Johnston, JA; Robinson, MD; Sullivan, MA | 1 |
| Koike, K; Yamamoto, Y | 1 |
| Astier, B; Bert, L; Chouvet, G; Denoroy, L; Lambás Señas, L; Lesourd, M; Muñoz, C; Renaud, B; Rentero, N; Schmitt, P; Soulière, F; Urbain, N | 1 |
| Inagaki, H; Kiyokawa, Y; Mori, Y; Takeuchi, Y | 1 |
| Bruckmann, W; De Vry, J; Rutten, K; Tzschentke, TM; Van Der Kam, EL | 1 |
| Borns-Weil, S | 1 |
2 review(s) available for clonidine and buspirone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Advances in non-nicotine pharmacotherapy for smoking cessation.
Topics: Antidepressive Agents; Bupropion; Buspirone; Clonidine; Humans; Moclobemide; Narcotic Antagonists; Smoking Cessation | 2000 |
2 trial(s) available for clonidine and buspirone
| Article | Year |
|---|---|
Nonbenzodiazepine anxiolytics: clinical usefulness.
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clinical Trials as Topic; Clonidine; Double-Blind Method; Histamine H1 Antagonists; Humans; Pyrimidines | 1983 |
Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.
Topics: Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Anti-Anxiety Agents; Blood Pressure; Body Temperature; Buspirone; C-Peptide; Clonidine; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Growth Hormone; Heart Rate; Humans; Insulin; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Pyrimidines; Serotonin Antagonists | 1995 |
28 other study(ies) available for clonidine and buspirone
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
Topics: Amidohydrolases; Carbamates; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Piperazines; Stereoisomerism; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Potentiation of poststartle activity by conditioned fear: effects of anxiolytic and anxiogenic drugs.
Topics: Animals; Anti-Anxiety Agents; Arousal; Buspirone; Clonidine; Conditioning, Classical; Diazepam; Dose-Response Relationship, Drug; Fear; Male; Rats; Rats, Inbred Strains; Reflex, Startle; Xylazine; Yohimbine | 1991 |
Effects of anxiety drugs on the modification of the acoustic startle reflex by noise gaps.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Acoustic Stimulation; Animals; Anti-Anxiety Agents; Buspirone; Carbolines; Clonidine; Male; Midazolam; Rats; Reflex, Acoustic; Tetrahydronaphthalenes | 1991 |
Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--II. Effects of acute administration of 1-PP and long-term administration of tandospirone on noradrenergic neurotransmission.
Topics: Animals; Anti-Anxiety Agents; Brain; Buspirone; Clonidine; Electric Stimulation; GABA Antagonists; Isoindoles; Male; Neurons; Norepinephrine; Piperazines; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha | 1991 |
Ipsapirone and 1-(2-pyrimidinyl)-piperazine increase rat locus coeruleus noradrenergic activity.
Topics: Action Potentials; Animals; Brain; Buspirone; Clonidine; Dose-Response Relationship, Drug; Locus Coeruleus; Male; Norepinephrine; Pyrimidines; Rats; Rats, Inbred Strains | 1990 |
Electrophysiological and microiontophoretic studies with buspirone: influence on the firing rate of central monoaminergic neurons and their responsiveness to dopamine, clonidine or GABA.
Topics: Animals; Brain; Buspirone; Clonidine; Dopamine; gamma-Aminobutyric Acid; Iontophoresis; Locus Coeruleus; Male; Neurons; Neurosecretory Systems; Norepinephrine; Rats; Rats, Inbred Strains | 1987 |
A metabolite of buspirone increases locus coeruleus activity via alpha 2-receptor blockade.
Topics: Action Potentials; Adrenergic alpha-Antagonists; Animals; Buspirone; Clonidine; Dose-Response Relationship, Drug; Locus Coeruleus; Male; Rats; Rats, Inbred Strains; Receptors, Adrenergic; Receptors, Adrenergic, alpha | 1989 |
Pharmacological evidence for the involvement of 1-(2-pyridinyl)-piperazine (1-PmP) in the interaction of buspirone or gepirone with noradrenergic systems.
Topics: Animals; Anti-Anxiety Agents; Body Temperature; Buspirone; Clonidine; Male; Mice; Motor Activity; Oxidation-Reduction; Piperazines; Pyridines; Pyrimidines | 1987 |
Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone.
Topics: Adrenergic alpha-Antagonists; Animals; Buspirone; Cerebral Cortex; Clonidine; Gastrointestinal Transit; Hypnotics and Sedatives; Male; Methoxyhydroxyphenylglycol; Rats; Reflex; Yohimbine | 1988 |
The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP).
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Animals; Anti-Anxiety Agents; Buspirone; Chromatography, High Pressure Liquid; Clonidine; Drug Interactions; Gastrointestinal Transit; Injections, Intravenous; Male; Pyrimidines; Rats | 1988 |
Tissue-dependent alpha adrenoceptor activity of buspirone and related compounds.
Topics: Animals; Buspirone; Cerebral Cortex; Clonidine; Guinea Pigs; Male; Norepinephrine; Phenylephrine; Prazosin; Pyrimidines; Rabbits; Rats; Receptors, Adrenergic, alpha; Vas Deferens | 1987 |
Psychopharmacologic treatment of anxiety.
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Buspirone; Clonidine; Humans; Panic; Phenothiazines; Phobic Disorders; Pyrimidines | 1983 |
The effects of benzodiazepine and non-benzodiazepine anxiolytics on locus coeruleus unit activity.
Topics: Action Potentials; Animals; Anti-Anxiety Agents; Benzodiazepines; Buspirone; Clonidine; Dextroamphetamine; Electric Conductivity; Locus Coeruleus; Male; Neurons; Pyrimidines; Rats; Rats, Inbred Strains; Structure-Activity Relationship; Synaptic Transmission | 1983 |
Antagonism of clonidine antinociception by buspirone and 1-(2-pyrimidinyl)-piperazine.
Topics: Analgesics; Animals; Anti-Anxiety Agents; Buspirone; Clonidine; Male; Mice | 1994 |
[Potentiating effect of clonidine on anxiolytic action of buspirone in rats].
Topics: Animals; Anxiety; Buspirone; Clonidine; Drug Synergism; Male; Rats; Rats, Wistar | 1993 |
Characterization of alpha1-adrenoceptor-mediated contraction in the mouse thoracic aorta.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Buspirone; Clonidine; Dioxanes; Dose-Response Relationship, Drug; Epinephrine; In Vitro Techniques; Male; Methoxamine; Mice; Models, Biological; Norepinephrine; Phenylephrine; Piperazines; Prazosin; Receptors, Adrenergic, alpha-1; Serotonin Receptor Agonists; Statistics as Topic; Vasoconstriction | 2001 |
In vivo comparison of two 5-HT1A receptors agonists alnespirone (S-20499) and buspirone on locus coeruleus neuronal activity.
Topics: Animals; Buspirone; Clonidine; Electrophysiology; Locus Coeruleus; Male; Microdialysis; Neurons; Norepinephrine; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Receptor Agonists; Spiro Compounds; Time Factors | 2003 |
The alarm pheromone in male rats as a unique anxiety model: psychopharmacological evidence using anxiolytics.
Topics: Administration, Inhalation; Animals; Anti-Anxiety Agents; Anxiety; Buspirone; Clonidine; Disease Models, Animal; Male; Midazolam; Phenelzine; Pheromones; Propranolol; Pyrimidines; Pyrroles; Rats; Rats, Wistar; Reflex, Startle | 2010 |
The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats.
Topics: Animals; Brain; Buspirone; Choice Behavior; Clonidine; Cocaine; Conditioning, Classical; Dose-Response Relationship, Drug; Drug Synergism; Illicit Drugs; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Nicotine; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Social Environment; Substance-Related Disorders | 2011 |
Animal Behavior Case of the Month.
Topics: Aggression; Animals; Behavior Therapy; Behavior, Animal; Buspirone; Clonidine; Dogs; Female; Fluoxetine | 2019 |